

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TenNor Therapeutics (Suzhou) Limited

丹諾醫藥(蘇州)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6872)

VOLUNTARY ANNOUNCEMENT H SHARE REPURCHASE PLAN

This announcement is made by TenNor Therapeutics (Suzhou) Limited (the **“Company”**) on a voluntary basis.

Pursuant to the resolution passed by the shareholders of the Company (the **“Shareholders”**) at the 2026 second extraordinary general meeting of the Company (the **“EGM”**) held on October 23, 2026, the board (the **“Board”**) of directors (the **“Directors”**) of the Company has been granted a general mandate to repurchase H shares of the Company (the **“H Shares”**) (the **“Repurchase Mandate”**). The maximum number of H Shares that may be repurchased shall not exceed 5,232,892 H Shares, representing no more than 10% of the total number of issued H Shares (excluding any treasury shares) as at the date on which the relevant resolution was passed at the EGM (i.e. October 23, 2026).

Given that the current market price of the H Shares does not fully reflect the Company's intrinsic value and business development prospects, the Board hereby announces that it intends to exercise its powers under the Repurchase Mandate. With the approval of the Board, the Company will repurchase H Shares in the open market from time to time based on market conditions, with an aggregate repurchase amount not exceeding RMB50 million (the **“H Share Repurchase Plan”**). The H Share Repurchase Plan will be funded by the Company's internal resources.

The Board believes that the repurchase of H Shares under the current market conditions will demonstrate the Company's confidence in its own business outlook and prospects, which will ultimately benefit the Company and create value for the Shareholders. The implementation of the H Share Repurchase Plan will not have any material adverse effect on the financial position of the Company or its ordinary course of business. Accordingly, the Board considers that the implementation of the H Share Repurchase Plan is in the interests of the Company and the Shareholders as a whole.

The Company will repurchase H Shares in accordance with the Articles of Association of the Company, the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the Codes on Takeovers and Mergers and Share Buy-backs, and other applicable laws and regulations. The implementation of the H Share Repurchase Plan shall be subject to the grant of a general mandate to the Board to repurchase H Shares by the Shareholders at the relevant time.

Shareholders and potential investors of the Company should note that the repurchase of H Shares by the Company will be subject to market conditions. There is no assurance of the timing, quantity or price of any repurchases, or whether the Company will repurchase any H Shares. Shareholders and potential investors of the Company are therefore advised to exercise caution when dealing in the shares of the Company.

By order of the Board
TenNor Therapeutics (Suzhou) Limited
Dr. Ma Zhenkun
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, October 26, 2026

As at the date of this announcement, the Board comprises: (i) Dr. Ma Zhenkun as an executive Director; (ii) Dr. Song Gaoguang as a non-executive Director; and (iii) Mr. Lee Wai Kong, Albert, Dr. Ni Lin and Dr. Li Leping as independent non-executive Directors.